A formation of group of inherited immune disorders in which lymphocyte functions are impaired and lymphocyte numbers may be diminished is called Combined immune deficiencies (CIDs).These disorders affect the T-cells which disturbs their ability to provide assistance in production of antibodies and therefore causing decreased immunoglobulins. Combined immune deficiency (CID) as a result of defects caused by the gene mutations in the immune system.
The Covid-19 has a positive impact on the Combined Immune Deficiency (CID) Market. The patients with immune deficiency disorders are more prone to developing infectious diseases. The Covid-19 virus has a significant impact on the immune system leading to rising no. of patients with immune deficiency disorders seek consistent treatment.
Combined Immune Deficiency (CID) Market: Drivers and Restraints
The prevalence of immunodeficiency diseases is on a rise across the globe. According to a study conducted by American academy of pediatrics, the calculated prevalence of diagnosed primary immune deficiency was 1 in 2000 children and 1 in 600 households. This rise in research and development activities that focus on identifying the gene that could cause combined immune deficiency are expected to accelerate new drug development and gene-sequencing. This is expected to drive the growth of the Combined Immune Deficiency (CID) Market.
However, the lack of awareness amongst end users and the non-availability of diagnostic facilities in underdeveloped and developing countries with resource constraints is likely to leave this disease under recognized. This will in-turn restrict the growth of the Combined Immune Deficiency (CID) market. Additionally, lack of adequate reimbursement and high cost of the therapies required for treatment may also restrain the growth of the Combined Immune Deficiency (CID) market.
Know More Details About the Report
Combined Immune Deficiency (CID) Market: Overview
Combined Immune Deficiency (CID) Market is expected to witness substantial growth as a result of increasing incidence of Combined Immune Deficiency globally during the forecast period.
Based on therapy type, the gene therapy is expected to dominate the Combined Immune Deficiency (CID) Market during the forecast period. The promising results of recent clinical trials is expected to make gene therapy prominent in the treatment of combined immune deficiency
In the end user segment, the hospitals are expected to hold the largest share in the Combined Immune Deficiency (CID) Market. However, the rigorous research and development activities and the increased focus of the government to encounter immune deficiency disorders is expected to lead considerable growth in the research and development segment.
Combined Immune Deficiency (CID) Market: Regional-Wise Outlook
Geographically, the Combined Immune Deficiency (CID) Market is segmented into seven regions viz. East Asia, South Asia, Latin America, Europe, Oceania, North America and Middle East & Africa. North America is expected to hold the largest market share, this is due to rise in prevalence of immune deficiency disorders in this region.
According to a study conducted by immune deficiency foundation, suggested that the prevalence of diagnosed primary immune deficiency in U.S. is approximately 1 in 1,200 persons. Moreover, the rise is healthcare expenditure and the presence of well-established healthcare system and key players are driving the growth of the Combined Immune Deficiency (CID) market in this region.
East Asia and South Asia is anticipated to experience considerable growth in the Combined Immune Deficiency (CID) market during the forecast period. The rising efforts by the medical system by increasing R&D activities to advance the healthcare system is leading to considerable growth of Combined Immune Deficiency (CID) Market in this region. For instance, the Indian council of medical research funded 2 research centers for advanced research in primary immune deficiency. These centers are actively involved since 2010 in taking care of the patients with primary immuno deficiency.
Avail customized purchase options for your needs
Combined Immune Deficiency (CID) Market: Key players
Some of the players identified in the Combined Immune Deficiency (CID) Market include:
- LFB SA
- Shire plc
- Kedrion Biopharma Inc
- CSL Behring
- China Biologic Products Holdings, Inc
- Grifols, S.A
- Biotest AG,
- Baxter International Inc.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology Matrix
- Value Chain
Regional analysis of the Combined Immune Deficiency market report includes
- North America
- Latin America
- South Asia
- East Asia
- Middle East and Africa
An Adaptive Approach to Modern-day Research Needs
Combined Immune Deficiency marketReport Highlights:
- Overview of Global Healthcare Market
- Evolution of the technology
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint.
Combined Immune Deficiency (CID) Market: Segmentation
Tentatively, the global Combined Immune Deficiency (CID) Market has been segmented on the basis of disease type, therapy type and end user.
Based on disease type, the global Combined Immune Deficiency (CID) Market is segmented as:
- Antibody Deficiency
- Cellular Immunodeficiency
- Innate Immune Disorders
Based on therapy type, the global Combined Immune Deficiency (CID) Market is segmented as:
- Immunoglobulin Replacement Therapy
- Bone marrow transplant
- Stem cell transplant
- Lung transplant
- Gene therapy
Based on end user, the global Combined Immune Deficiency (CID) Market is segmented as:
- Ambulatory surgical care
- Research and development institutes
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
The Rise of Intelligent Packaging
Personalized, Connected and Sustainable
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.